OncoMed Pharma (OMED) Doses First Patient in Phase 1b Trial of Anti-DLL4/VEGF Bispecific Antibody
Tweet Send to a Friend
OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) announced dosing of the first patient in a Phase 1b clinical trial of anti-DLL4/VEGF bispecific ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE